Oral presentation to include preclinical profile for ORX750, Centessa’s first orexin agonist development candidate for the treatment of narcolepsy and...
BOSTON and LONDON, May 22, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to...
Investegate announcements from Centessa Pharmaceuticals plc, Centessa Pharmaceuticals Reports Recent Business Progress and Financial Results for the Fourth Quarter and Full-Year 2022
Investegate announcements from Centessa Pharmaceuticals plc, Centessa Pharmaceuticals Announces Addition of Patrick Yue, MD, as Senior Vice President of Clinical Development, Innovative Medicines
Investegate announcements from Centessa Pharmaceuticals plc, Centessa Pharmaceuticals Announces Presentation at the SVB Securities Global Biopharma Conference
Investegate announcements from Centessa Pharmaceuticals plc, Centessa Pharmaceuticals Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of LB101, First LockBody® Candidate, for Solid Tumors
Investegate announcements from Centessa Pharmaceuticals plc, Centessa Pharmaceuticals Announces Additional 18-Months of Continued Treatment Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia